Reirradiation of head and neck cancer: Long-term disease control and toxicity
- PMID: 28263446
- PMCID: PMC5485062
- DOI: 10.1002/hed.24733
Reirradiation of head and neck cancer: Long-term disease control and toxicity
Abstract
Background: The purpose of this study was to report long-term disease control and late radiation toxicity for patients reirradiated for head and neck cancer.
Methods: We conducted a retrospective analysis of 137 patients reirradiated with a prescribed dose ≥45 Gy between 1986 and 2013 for a recurrent or second primary malignancy. Endpoints were locoregional control, overall survival (OS), and grade ≥4 late complications according to European Organization for Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group (RTOG) criteria.
Results: Five-year locoregional control rates were 46% for patients reirradiated postoperatively versus 20% for patients who underwent reirradiation as the primary treatment (p < .05). Sixteen cases of serious (grade ≥4) late toxicity were seen in 11 patients (actuarial 28% at 5 years). In patients reirradiated with intensity-modulated radiotherapy (IMRT), a borderline improved locoregional control was observed (49% vs 36%; p = .07), whereas late complication rates did not differ.
Conclusion: Reirradiation should be considered for patients with a recurrent or second primary head and neck cancer, especially postoperatively, if indicated. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1122-1130, 2017.
Keywords: disease control; head and neck cancer; intensity-modulated radiotherapy (IMRT); late toxicity; reirradiation.
© 2017 The Authors Head & Neck Published by Wiley Periodicals, Inc.
Figures




Similar articles
-
Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis.Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):606-617. doi: 10.1016/j.ijrobp.2017.11.036. Epub 2017 Dec 1. Int J Radiat Oncol Biol Phys. 2018. PMID: 29413274 Free PMC article.
-
Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma.Head Neck. 2017 Mar;39(3):533-540. doi: 10.1002/hed.24645. Epub 2016 Nov 29. Head Neck. 2017. PMID: 27898191
-
High-dose reirradiation with intensity-modulated radiotherapy for recurrent head-and-neck cancer: disease control, survival and toxicity.Radiother Oncol. 2014 Jun;111(3):388-92. doi: 10.1016/j.radonc.2014.04.018. Epub 2014 Jul 3. Radiother Oncol. 2014. PMID: 24998706
-
Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer: Meta-analysis and systematic review.Head Neck. 2020 Sep;42(9):2473-2485. doi: 10.1002/hed.26264. Epub 2020 May 21. Head Neck. 2020. PMID: 32437021
-
Reirradiation for recurrent head and neck cancer.Expert Rev Anticancer Ther. 2012 Sep;12(9):1177-89. doi: 10.1586/era.12.97. Expert Rev Anticancer Ther. 2012. PMID: 23098118 Review.
Cited by
-
Re-irradiation for head and neck cancer: outcome and toxicity analysis using a prospective single institution database.Front Oncol. 2023 Jun 29;13:1175609. doi: 10.3389/fonc.2023.1175609. eCollection 2023. Front Oncol. 2023. PMID: 37456239 Free PMC article.
-
Permanent Interstitial Brachytherapy for Previously Irradiated Head and Neck Cancer.Cureus. 2018 Apr 22;10(4):e2517. doi: 10.7759/cureus.2517. Cureus. 2018. PMID: 29942720 Free PMC article.
-
The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.Radiat Oncol. 2020 Apr 16;15(1):81. doi: 10.1186/s13014-020-01531-5. Radiat Oncol. 2020. PMID: 32299456 Free PMC article.
-
Interprofessional Team-Based Whole-Course Enteral Nutrition in the Peri-Radiation Therapy Period for Esophageal Cancer.Clin J Oncol Nurs. 2025 May 19;29(3):E88-E96. doi: 10.1188/25.CJON.E88-E96. Clin J Oncol Nurs. 2025. PMID: 40401829 Clinical Trial.
-
Re-irradiation for recurrent or second primary head and neck cancer.Radiat Oncol J. 2021 Dec;39(4):279-287. doi: 10.3857/roj.2021.00640. Epub 2021 Dec 7. Radiat Oncol J. 2021. PMID: 34986549 Free PMC article.
References
-
- Blanchard P, Baujat B, Holostenco V, et al. Meta‐analysis of chemotherapy in head and neck cancer (MACH‐NC): a comprehensive analysis by tumour site. Radiother Oncol 2011;100:33–40. - PubMed
-
- Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9‐year, 337‐patient, multi‐institutional experience. Ann Oncol 2004;15:1179–1186. - PubMed
-
- Schwartz LH, Ozsahin M, Zhang GN, et al. Synchronous and metachronous head and neck carcinomas. Cancer 1994;74:1933–1938. - PubMed
-
- Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110(3 Pt 2 Suppl 93):1–18. - PubMed
-
- McDonald MW, Lawson J, Garg MK, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology‐head and neck cancer. Int J Radiat Oncol Biol Phys 2011;80:1292–1298. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical